Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ocular Technologies SARL; Sun Pharma Global FZE
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• History of dry eye syndrome (KCS) for a period of at least 6 months

• Clinical diagnosis of bilateral KCS

• Lissamine green conjunctival staining sum score of ≥ 3 to ≤ 9 out of a total possible score of 12 (scoring excludes superior zones 2 and 4) in the same eye at both the Screening and Baseline Visits.

• Global symptom score (SANDE) ≥ 40 mm at both the Screening and Baseline Visits

• Corrected Snellen visual acuity (VA) of better than 20/200 in each eye.

Exclusion Criteria:

• Use of cyclosporine ophthalmic emulsion 0.05% (Restasis®) within 3 months prior to the Screening Visit.

• Previous treatment failure (lack of efficacy) with cyclosporine ophthalmic emulsion 0.05% (Restasis).

• Diagnosis of Sjögren's disease ˃ 5 years prior to the Screening Visit.

• Clinical diagnosis or any history of seasonal and/or perennial allergic conjunctivitis.

• Use of systemic or topical medications within 7 days prior to the Screening Visit or during the study period that are known to cause dry eye.

• Use of any topical ophthalmic medications, prescription (including anti-glaucoma medications) or over the counter (including artificial tears), other than the assigned study medication during the study period.

• Current active eye disease other than dry wyw syndrome (i.e., any disease for which topical or systemic ophthalmic medication is necessary).

• History of herpes keratitis.

• Corneal transplant

• Corneal refractive surgery within 6 months prior to the Screening Visit or postoperative refractive surgery symptoms of dryness that have not resolved.

• Cataract surgery within 3 months prior to the Screening Visit.